3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Cholangiocarcinoma
2
Liver Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Bevacizumab
23
Sorafenib
20
Doxorubicin
14
Gemcitabine
11
durvalumab
10
Oxaliplatin
10
Fluorouracil
10
Cisplatin
10
Capecitabine
9
Nivolumab
8
pembrolizumab
6
Sunitinib
6
tremelimumab
5
atezolizumab
5
Radiofrequency Ablation
5
Neoadjuvant Therapy
5
Leucovorin
5
lenvatinib
4
aldesleukin
4
Thalidomide
4
Radiotherapy
4
Radiosurgery
4
Everolimus
4
Erlotinib Hydrochloride
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
regorafenib
3
camrelizumab
3
apatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liver Neoplasms
×
derazantinib
×
Clear all
NCT03230318
2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2
Completed
148 enrolled
15 charts